In prognostics, Van Spaendonck-Zwarts et al. demonstrated that the prevalence of mortality, heart transplantation and malignant ventricular arrhythmias was higher among DCM patients with a mutation in the phospholamban (PLN) or LMNA gene, compared with DCM patients who did not carry a mutation in diagnostically screened genes [23]. Here, LMNA is linked to familial dilated cardiomyopathy.